NCT04268706
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) treatment 2 active_not_recruiting NCT05352828
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy treatment 1 active_not_recruiting NCT01703949
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma treatment 2 recruiting NCT03213665
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT04134325
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma treatment 0 active_not_recruiting NCT03016871
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL treatment 2 active_not_recruiting NCT04640779
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma treatment 1 recruiting NCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL treatment 2 recruiting NCT03259503
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant treatment 1 active_not_recruiting NCT01921387
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies treatment 1 / 2 completed NCT03013933
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 1 completed NCT05595447
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma treatment 2 / 3 recruiting NCT04681105
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies treatment 1 active_not_recruiting NCT04052997
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 2 completed NCT01619761
NK Cells in Cord Blood Transplantation treatment 1 unknown_status NCT00860171
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma No drug interventions treatment 1 terminated NCT02181478
Intra-Osseous Co-Transplant of UCB and hMSC treatment 0 completed NCT04871607
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma treatment 2 recruiting NCT02456675
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma treatment 2 terminated NCT02227199
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 1 / 2 active_not_recruiting NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT03432741
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer treatment 1 suspended NCT02304458
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas treatment 1 / 2 completed NCT03730363
Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma treatment 1 completed NCT01701986
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma treatment 1 / 2 completed NCT02254239
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 1 terminated NCT04776265
RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT No drug interventions Not Available Not Available recruiting NCT00789776
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer treatment 1 / 2 completed NCT02744612
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma treatment 2 active_not_recruiting NCT01231412
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant treatment 3 completed NCT03057795
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma treatment 2 active_not_recruiting NCT00005803
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma treatment 1 / 2 completed NCT05272384
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma treatment 1 recruiting NCT02869633
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant treatment 2 completed NCT00075478
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer treatment 3 completed NCT04938232
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL treatment 2 active_not_recruiting NCT03739606
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer treatment 2 withdrawn NCT03739619
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma treatment 1 / 2 active_not_recruiting NCT01393717
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma treatment 2 completed NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial treatment 1 terminated NCT06487624
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors treatment 1 not_yet_recruiting NCT05137886
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma treatment 2 recruiting NCT02824029
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma treatment 2 active_not_recruiting NCT01897012
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas treatment 1 completed